ID   UBP37_HUMAN             Reviewed;         979 AA.
AC   Q86T82; A2RUQ8; B7ZM38; B7ZM41; E9PHL3; Q2KHT2; Q53S10; Q7Z3A5;
AC   Q9HCH8;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 2.
DT   10-MAY-2017, entry version 127.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase 37;
DE            EC=3.4.19.12 {ECO:0000269|PubMed:27296872};
DE   AltName: Full=Deubiquitinating enzyme 37;
DE   AltName: Full=Ubiquitin thioesterase 37;
DE   AltName: Full=Ubiquitin-specific-processing protease 37;
GN   Name=USP37; Synonyms=KIAA1594;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   SER-979.
RC   TISSUE=Spinal cord;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT SER-979.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   SER-979.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 49-979 (ISOFORM 1), AND
RP   VARIANT SER-979.
RC   TISSUE=Brain;
RX   PubMed=10997877; DOI=10.1093/dnares/7.4.271;
RA   Nagase T., Kikuno R., Nakayama M., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes.
RT   XVIII. The complete sequences of 100 new cDNA clones from brain which
RT   code for large proteins in vitro.";
RL   DNA Res. 7:273-281(2000).
RN   [6]
RP   TISSUE SPECIFICITY, AND ENZYME ACTIVITY.
RX   PubMed=14715245; DOI=10.1016/j.bbrc.2003.12.050;
RA   Quesada V., Diaz-Perales A., Gutierrez-Fernandez A., Garabaya C.,
RA   Cal S., Lopez-Otin C.;
RT   "Cloning and enzymatic analysis of 22 novel human ubiquitin-specific
RT   proteases.";
RL   Biochem. Biophys. Res. Commun. 314:54-62(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-650 AND SER-652, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   FUNCTION, UBIQUITINATION, PHOSPHORYLATION AT SER-628 BY CDK2, DOMAIN
RP   KEN BOX 3, DEVELOPMENTAL STAGE, INDUCTION, INTERACTION WITH FZR1, AND
RP   MUTAGENESIS OF 32-LYS--ASN-34; 71-ARG-LEU-74; 96-ARG-LEU-99;
RP   160-ARG-LEU-163; 221-LYS--ASN-223; CYS-350; 782-LYS--ASN-784 AND
RP   SER-628.
RX   PubMed=21596315; DOI=10.1016/j.molcel.2011.03.027;
RA   Huang X., Summers M.K., Pham V., Lill J.R., Liu J., Lee G.,
RA   Kirkpatrick D.S., Jackson P.K., Fang G., Dixit V.M.;
RT   "Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and
RT   promote S phase entry.";
RL   Mol. Cell 42:511-523(2011).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-170; SER-210 AND
RP   SER-770, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   CATALYTIC ACTIVITY, MUTAGENESIS OF CYS-350, INTERACTION WITH CDT1, AND
RP   FUNCTION.
RX   PubMed=27296872; DOI=10.1016/j.molonc.2016.05.008;
RA   Hernandez-Perez S., Cabrera E., Amoedo H., Rodriguez-Acebes S.,
RA   Koundrioukoff S., Debatisse M., Mendez J., Freire R.;
RT   "USP37 deubiquitinates Cdt1 and contributes to regulate DNA
RT   replication.";
RL   Mol. Oncol. 10:1196-1206(2016).
CC   -!- FUNCTION: Deubiquitinase that antagonizes the anaphase-promoting
CC       complex (APC/C) during G1/S transition by mediating
CC       deubiquitination of cyclin-A (CCNA1 and CCNA2), thereby promoting
CC       S phase entry. Specifically mediates deubiquitination of 'Lys-11'-
CC       linked polyubiquitin chains, a specific ubiquitin-linkage type
CC       mediated by the APC/C complex. Also mediates deubiquitination of
CC       'Lys-48'-linked polyubiquitin chains in vitro. Phosphorylation at
CC       Ser-628 during G1/S phase maximizes the deubiquitinase activity,
CC       leading to prevent degradation of cyclin-A (CCNA1 and CCNA2)
CC       (PubMed:21596315). Plays an important role in the regulation of
CC       DNA replication by stabilizing the licensing factor CDT1
CC       (PubMed:27296872). {ECO:0000269|PubMed:21596315,
CC       ECO:0000269|PubMed:27296872}.
CC   -!- CATALYTIC ACTIVITY: Thiol-dependent hydrolysis of ester,
CC       thioester, amide, peptide and isopeptide bonds formed by the C-
CC       terminal Gly of ubiquitin (a 76-residue protein attached to
CC       proteins as an intracellular targeting signal).
CC       {ECO:0000269|PubMed:14715245, ECO:0000269|PubMed:27296872}.
CC   -!- SUBUNIT: Interacts with FZR1/CDH1 (PubMed:21596315). Interacts
CC       with CDT1 (PubMed:27296872). {ECO:0000269|PubMed:21596315,
CC       ECO:0000269|PubMed:27296872}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q86T82-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q86T82-2; Sequence=VSP_041740, VSP_041741;
CC   -!- TISSUE SPECIFICITY: Expressed in brain and prostate.
CC       {ECO:0000269|PubMed:14715245}.
CC   -!- DEVELOPMENTAL STAGE: Induced in G1 phase, accumulates at G1/S
CC       transition, and degraded in late mitosis following ubiquitination
CC       and degradation by the APC(CDH1) complex.
CC       {ECO:0000269|PubMed:21596315}.
CC   -!- INDUCTION: Induced by E2F transcription factors in G1.
CC       {ECO:0000269|PubMed:21596315}.
CC   -!- DOMAIN: The KEN box 3 is required for interaction with FZR1/CDH1
CC       and is essential for APC(CDH1)-mediated ubiquitination.
CC       {ECO:0000269|PubMed:21596315}.
CC   -!- PTM: Polyubiquitinated via 'Lys-11'-linked ubiquitin by the
CC       APC(CDH1) complex during late mitosis, leading to its degradation.
CC       Able to mediate auto-deubiquitination.
CC       {ECO:0000269|PubMed:21596315}.
CC   -!- PTM: Phosphorylated at Ser-628 by CDK2 during G1/S phase but not
CC       during mitosis; phosphorylation at Ser-628 is required for
CC       deubiquitinase activity. Also polyubiquitinated during early G1
CC       phase, without leading to degradation.
CC       {ECO:0000269|PubMed:21596315}.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAY14887.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL832645; CAD89955.1; -; mRNA.
DR   EMBL; BX538024; CAD97970.1; -; mRNA.
DR   EMBL; AC012510; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073838; AAY14887.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471063; EAW70621.1; -; Genomic_DNA.
DR   EMBL; BC112901; AAI12902.1; -; mRNA.
DR   EMBL; BC133007; AAI33008.1; -; mRNA.
DR   EMBL; BC133009; AAI33010.1; -; mRNA.
DR   EMBL; BC144249; AAI44250.1; -; mRNA.
DR   EMBL; BC144252; AAI44253.1; -; mRNA.
DR   EMBL; AB046814; BAB13420.1; -; mRNA.
DR   RefSeq; NP_065986.2; NM_020935.2.
DR   RefSeq; XP_005246777.1; XM_005246720.2. [Q86T82-1]
DR   RefSeq; XP_005246778.1; XM_005246721.3. [Q86T82-1]
DR   RefSeq; XP_005246779.1; XM_005246722.3. [Q86T82-1]
DR   RefSeq; XP_011509840.1; XM_011511538.2. [Q86T82-1]
DR   UniGene; Hs.166068; -.
DR   PDB; 3U12; X-ray; 2.08 A; A/B=4-125.
DR   PDBsum; 3U12; -.
DR   ProteinModelPortal; Q86T82; -.
DR   SMR; Q86T82; -.
DR   BioGrid; 121720; 98.
DR   IntAct; Q86T82; 3.
DR   MINT; MINT-4720282; -.
DR   STRING; 9606.ENSP00000258399; -.
DR   MEROPS; C19.053; -.
DR   iPTMnet; Q86T82; -.
DR   PhosphoSitePlus; Q86T82; -.
DR   BioMuta; USP37; -.
DR   DMDM; 300669620; -.
DR   EPD; Q86T82; -.
DR   MaxQB; Q86T82; -.
DR   PaxDb; Q86T82; -.
DR   PeptideAtlas; Q86T82; -.
DR   PRIDE; Q86T82; -.
DR   DNASU; 57695; -.
DR   Ensembl; ENST00000258399; ENSP00000258399; ENSG00000135913. [Q86T82-1]
DR   Ensembl; ENST00000415516; ENSP00000400902; ENSG00000135913. [Q86T82-2]
DR   Ensembl; ENST00000418019; ENSP00000396585; ENSG00000135913. [Q86T82-1]
DR   Ensembl; ENST00000454775; ENSP00000393662; ENSG00000135913. [Q86T82-1]
DR   GeneID; 57695; -.
DR   KEGG; hsa:57695; -.
DR   UCSC; uc002vie.3; human. [Q86T82-1]
DR   CTD; 57695; -.
DR   DisGeNET; 57695; -.
DR   GeneCards; USP37; -.
DR   HGNC; HGNC:20063; USP37.
DR   HPA; HPA045160; -.
DR   neXtProt; NX_Q86T82; -.
DR   OpenTargets; ENSG00000135913; -.
DR   PharmGKB; PA134928706; -.
DR   eggNOG; KOG1868; Eukaryota.
DR   eggNOG; ENOG410XP8T; LUCA.
DR   GeneTree; ENSGT00440000033542; -.
DR   HOVERGEN; HBG055893; -.
DR   InParanoid; Q86T82; -.
DR   KO; K11850; -.
DR   OMA; WLQQYDM; -.
DR   OrthoDB; EOG091G01DZ; -.
DR   PhylomeDB; Q86T82; -.
DR   TreeFam; TF323032; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   ChiTaRS; USP37; human.
DR   GeneWiki; USP37; -.
DR   GenomeRNAi; 57695; -.
DR   PRO; PR:Q86T82; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000135913; -.
DR   CleanEx; HS_USP37; -.
DR   ExpressionAtlas; Q86T82; baseline and differential.
DR   Genevisible; Q86T82; HS.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:LIFEdb.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004843; F:thiol-dependent ubiquitin-specific protease activity; IDA:UniProtKB.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; TAS:Reactome.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:FlyBase.
DR   GO; GO:0035871; P:protein K11-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0071108; P:protein K48-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0006275; P:regulation of DNA replication; IMP:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   CDD; cd13312; PH_USP37_like; 1.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR003903; UIM_dom.
DR   InterPro; IPR032069; USP37-like_PH.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   Pfam; PF00443; UCH; 1.
DR   Pfam; PF16674; UCH_N; 1.
DR   Pfam; PF02809; UIM; 3.
DR   SMART; SM00726; UIM; 4.
DR   PROSITE; PS50330; UIM; 3.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Cell division;
KW   Complete proteome; Hydrolase; Mitosis; Phosphoprotein; Polymorphism;
KW   Protease; Reference proteome; Repeat; Thiol protease; Ubl conjugation;
KW   Ubl conjugation pathway.
FT   CHAIN         1    979       Ubiquitin carboxyl-terminal hydrolase 37.
FT                                /FTId=PRO_0000080667.
FT   DOMAIN      341    951       USP.
FT   DOMAIN      704    723       UIM 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00213}.
FT   DOMAIN      806    825       UIM 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00213}.
FT   DOMAIN      828    847       UIM 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00213}.
FT   MOTIF        32     34       KEN box 1.
FT   MOTIF        71     79       D-box 1.
FT   MOTIF        96    105       D-box 2.
FT   MOTIF       160    168       D-box 3.
FT   MOTIF       221    223       KEN box 2.
FT   MOTIF       782    784       KEN box 3.
FT   ACT_SITE    350    350       Nucleophile.
FT                                {ECO:0000269|PubMed:27296872}.
FT   ACT_SITE    906    906       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092, ECO:0000255|PROSITE-
FT                                ProRule:PRU10093}.
FT   MOD_RES     170    170       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     210    210       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     628    628       Phosphoserine; by CDK2.
FT                                {ECO:0000269|PubMed:21596315,
FT                                ECO:0000269|PubMed:27296872}.
FT   MOD_RES     650    650       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     652    652       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     770    770       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1     72       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041740.
FT   VAR_SEQ     612    634       ISRPLKASQMVNSCITSPSTPSK -> M (in isoform
FT                                2). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041741.
FT   VARIANT     979    979       L -> S (in dbSNP:rs6436058).
FT                                {ECO:0000269|PubMed:10997877,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_059752.
FT   MUTAGEN      32     34       KEN->AAA: No effect.
FT                                {ECO:0000269|PubMed:21596315}.
FT   MUTAGEN      71     74       RLML->ALMA: No effect.
FT                                {ECO:0000269|PubMed:21596315}.
FT   MUTAGEN      96     99       RLFL->ALFA: No effect.
FT                                {ECO:0000269|PubMed:21596315}.
FT   MUTAGEN     160    163       RKVL->AKVA: No effect.
FT                                {ECO:0000269|PubMed:21596315}.
FT   MUTAGEN     221    223       KEN->AAA: No effect.
FT                                {ECO:0000269|PubMed:21596315}.
FT   MUTAGEN     350    350       C->S: Abolishes deubiquitinase activity.
FT                                {ECO:0000269|PubMed:21596315}.
FT   MUTAGEN     628    628       S->A: Abolishes phosphorylation by CDK2,
FT                                leading to lower deubiquitinase activity.
FT                                {ECO:0000269|PubMed:21596315}.
FT   MUTAGEN     782    784       KEN->AAA: Impaired interaction with
FT                                FZR1/CDH1 and subsequent ubiquitination.
FT                                {ECO:0000269|PubMed:21596315}.
FT   CONFLICT    223    224       ND -> DG (in Ref. 1; CAD89955).
FT                                {ECO:0000305}.
FT   CONFLICT    345    345       N -> K (in Ref. 1; CAD97970).
FT                                {ECO:0000305}.
FT   CONFLICT    456    456       V -> I (in Ref. 1; CAD89955).
FT                                {ECO:0000305}.
FT   CONFLICT    552    552       F -> I (in Ref. 4; AAI44250).
FT                                {ECO:0000305}.
FT   CONFLICT    567    567       S -> I (in Ref. 4; AAI44253).
FT                                {ECO:0000305}.
FT   CONFLICT    576    576       N -> Y (in Ref. 4; AAI44253).
FT                                {ECO:0000305}.
FT   CONFLICT    731    731       K -> E (in Ref. 1; CAD97970).
FT                                {ECO:0000305}.
FT   CONFLICT    905    905       G -> D (in Ref. 1; CAD97970).
FT                                {ECO:0000305}.
FT   STRAND        5     14       {ECO:0000244|PDB:3U12}.
FT   TURN         15     17       {ECO:0000244|PDB:3U12}.
FT   STRAND       23     32       {ECO:0000244|PDB:3U12}.
FT   STRAND       35     42       {ECO:0000244|PDB:3U12}.
FT   STRAND       49     52       {ECO:0000244|PDB:3U12}.
FT   TURN         54     56       {ECO:0000244|PDB:3U12}.
FT   STRAND       57     64       {ECO:0000244|PDB:3U12}.
FT   STRAND       69     76       {ECO:0000244|PDB:3U12}.
FT   STRAND       81     88       {ECO:0000244|PDB:3U12}.
FT   HELIX        89    103       {ECO:0000244|PDB:3U12}.
SQ   SEQUENCE   979 AA;  110170 MW;  9F47F06A744EA449 CRC64;
     MSPLKIHGPI RIRSMQTGIT KWKEGSFEIV EKENKVSLVV HYNTGGIPRI FQLSHNIKNV
     VLRPSGAKQS RLMLTLQDNS FLSIDKVPSK DAEEMRLFLD AVHQNRLPAA MKPSQGSGSF
     GAILGSRTSQ KETSRQLSYS DNQASAKRGS LETKDDIPFR KVLGNPGRGS IKTVAGSGIA
     RTIPSLTSTS TPLRSGLLEN RTEKRKRMIS TGSELNEDYP KENDSSSNNK AMTDPSRKYL
     TSSREKQLSL KQSEENRTSG LLPLQSSSFY GSRAGSKEHS SGGTNLDRTN VSSQTPSAKR
     SLGFLPQPVP LSVKKLRCNQ DYTGWNKPRV PLSSHQQQQL QGFSNLGNTC YMNAILQSLF
     SLQSFANDLL KQGIPWKKIP LNALIRRFAH LLVKKDICNS ETKKDLLKKV KNAISATAER
     FSGYMQNDAH EFLSQCLDQL KEDMEKLNKT WKTEPVSGEE NSPDISATRA YTCPVITNLE
     FEVQHSIICK ACGEIIPKRE QFNDLSIDLP RRKKPLPPRS IQDSLDLFFR AEELEYSCEK
     CGGKCALVRH KFNRLPRVLI LHLKRYSFNV ALSLNNKIGQ QVIIPRYLTL SSHCTENTKP
     PFTLGWSAHM AISRPLKASQ MVNSCITSPS TPSKKFTFKS KSSLALCLDS DSEDELKRSV
     ALSQRLCEML GNEQQQEDLE KDSKLCPIEP DKSELENSGF DRMSEEELLA AVLEISKRDA
     SPSLSHEDDD KPTSSPDTGF AEDDIQEMPE NPDTMETEKP KTITELDPAS FTEITKDCDE
     NKENKTPEGS QGEVDWLQQY DMEREREEQE LQQALAQSLQ EQEAWEQKED DDLKRATELS
     LQEFNNSFVD ALGSDEDSGN EDVFDMEYTE AEAEELKRNA ETGNLPHSYR LISVVSHIGS
     TSSSGHYISD VYDIKKQAWF TYNDLEVSKI QEAAVQSDRD RSGYIFFYMH KEIFDELLET
     EKNSQSLSTE VGKTTRQAL
//
